274 related articles for article (PubMed ID: 16180117)
1. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.
Mager DE; Krzyzanski W
Pharm Res; 2005 Oct; 22(10):1589-96. PubMed ID: 16180117
[TBL] [Abstract][Full Text] [Related]
2. General Pharmacokinetic Features of Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Simulation-Based Study.
Bach T; Jiang Y; Zhang X; An G
J Clin Pharmacol; 2019 Mar; 59(3):394-405. PubMed ID: 30387863
[TBL] [Abstract][Full Text] [Related]
3. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.
Gibiansky L; Gibiansky E
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):803-12. PubMed ID: 19505189
[TBL] [Abstract][Full Text] [Related]
4. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976
[TBL] [Abstract][Full Text] [Related]
5. Target-mediated drug disposition model for drugs that bind to more than one target.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
[TBL] [Abstract][Full Text] [Related]
6. Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases.
Koch G; Jusko WJ; Schropp J
J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):27-42. PubMed ID: 28074396
[TBL] [Abstract][Full Text] [Related]
7. Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor.
Yan X; Chen Y; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):543-60. PubMed ID: 22926955
[TBL] [Abstract][Full Text] [Related]
8. Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition.
Marathe A; Van Wart S; Mager DE
J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):223-35. PubMed ID: 21165681
[TBL] [Abstract][Full Text] [Related]
9. Approximations of the target-mediated drug disposition model and identifiability of model parameters.
Gibiansky L; Gibiansky E; Kakkar T; Ma P
J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):573-91. PubMed ID: 19005743
[TBL] [Abstract][Full Text] [Related]
10. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):341-51. PubMed ID: 19578985
[TBL] [Abstract][Full Text] [Related]
11. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.
Yan X; Mager DE; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):25-47. PubMed ID: 20012173
[TBL] [Abstract][Full Text] [Related]
12. Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Minireview.
An G
J Clin Pharmacol; 2017 Feb; 57(2):137-150. PubMed ID: 27489162
[TBL] [Abstract][Full Text] [Related]
13. Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model.
Marathe A; Krzyzanski W; Mager DE
J Pharmacokinet Pharmacodyn; 2009 Jun; 36(3):199-219. PubMed ID: 19434483
[TBL] [Abstract][Full Text] [Related]
14. Target-mediated drug disposition and dynamics.
Mager DE
Biochem Pharmacol; 2006 Jun; 72(1):1-10. PubMed ID: 16469301
[TBL] [Abstract][Full Text] [Related]
15. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep.
Segrave AM; Mager DE; Charman SA; Edwards GA; Porter CJ
J Pharmacol Exp Ther; 2004 Jun; 309(3):1085-92. PubMed ID: 14872093
[TBL] [Abstract][Full Text] [Related]
17. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
18. Target-mediated exposure enhancement: a previously unexplored limit of TMDD.
Glassman PM; Muzykantov VR
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):411-420. PubMed ID: 32488574
[TBL] [Abstract][Full Text] [Related]
19. Asymptotic Analysis of a Target-Mediated Drug Disposition Model: Algorithmic and Traditional Approaches.
Patsatzis DG; Maris DT; Goussis DA
Bull Math Biol; 2016 Jun; 78(6):1121-61. PubMed ID: 27271122
[TBL] [Abstract][Full Text] [Related]
20. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.
Mager DE; Jusko WJ
J Pharmacokinet Pharmacodyn; 2001 Dec; 28(6):507-32. PubMed ID: 11999290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
